Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Workforce Problems Include Long Hiring Cycle, Large Temporary Staff

This article was originally published in The Tan Sheet

Executive Summary

A report on the state of FDA’s workforce finds that eight of 10 medical officers are temporary or term appointed and that it takes about six months to bring an employee onboard. FDA’s new Office of Human Resources is seeking to reduce the time to hire.

You may also be interested in...



Advisors Say FDA Funding Fails Science, Senators Pan Food Safety Plan

Members of the Senate say FDA's Food Protection Plan is not sufficient to improve the current U.S. food safety system, but an FDA advisory board says without additional resources "substantial weaknesses across the agency" will continue

False Claims Act Liability: Defendant’s Belief Claims Were False Matters, Supreme Court Finds

In unanimous decision, court backs whistleblowers’ fraud theory that SuperValu and Safeway defrauded Medicare and Medicaid by reporting higher retail prices than their discounted prices. BIO, AdvaMed and MIWG submitted amicus brief in support of the retail pharmacies.

DOJ Enforcement: Talking With US FDA Is Not Enough To Get Credit For Self-Disclosure

Remediation of a problem with FDA is one factor the DOJ considers in assessing whether a company gets credit for self-disclosure of misconduct prior to a criminal investigation, but it wants companies to come directly to the department to divulge wrongdoing.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel